Replies to post #1462 on Evoke Pharma Inc. (EVOK)

[dmsrz8]

Read the last sentence off the 8-k...and then stop talking...

“The FDA approval of GIMOTI allows Evoke to access its existing $5 million line of credit from EVERSANA, to support manufacturing and other aspects of GIMOTI’s commercialization. As of May 31, 2020, the Company’s cash and cash equivalents were approximately $4.7 million. Evoke believes, based on its current operating plan, that its cash and cash equivalents, together with the EVERSANA line of credit, will support the company’s operations into 2021, without consideration of potential GIMOTI revenue”

[QuitinMyJob]

Bell or Eric, whatever your name/alias is, one material event can change a company's financial position. When that filing was published they didn't have FDA approval so of course that note has to be added to their filing. They have a product now and less than 25 million shares. You do the math here. There is one other drug in this market. They have one competitor in a $2 billon market. Good luck on Monday, but I've got a feeling you you will be buying shares one way or another. ;-)